本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Iovance Biotherapeutics, Inc.

2.31
+0.11005.00%
盤後2.30-0.0101-0.44%19:37 EST
成交量:1,407.66萬
成交額:3,196.83萬
市值:9.17億
市盈率:-1.93
高:2.34
開:2.20
低:2.16
收:2.20
52周最高:9.30
52周最低:1.64
股本:3.97億
流通股本:3.04億
量比:1.64
換手率:4.63%
股息:- -
股息率:- -
每股收益(TTM):-1.1987
每股收益(LYR):-1.2839
淨資產收益率:-53.89%
總資產收益率:-27.12%
市淨率:1.31
市盈率(LYR):-1.80

資料載入中...

公司資料

公司名字:
Iovance Biotherapeutics, Inc.
交易所:
NASDAQ
成立時間:
2007
員工人數:
838
公司地址:
825 Industrial Road,Suite 100,San Carlos,California,United States
郵編:
94070
電話:
傳真:
- -
簡介:
Iovance Biotherapeutics, Inc.是一家新興的生物技術公司,專註於培養細胞,使用自體腫瘤浸潤淋巴細胞(TIL)治療轉移性黑色素瘤等實體瘤的細胞治療方法的發展和商業化。該公司於2007年9月17日在內華達州成立。

董事

名稱
職位
Frederick G. Vogt
Interim Chief Executive Officer and President, General Counsel; Director
Iain Dukes
Chairman of the Board
Athena Countouriotis
Director
Michael Weiser
Director
Ryan D. Maynard
Director
Wayne P. Rothbaum
Director
Wendy L. Yarno
Director

股東

名稱
職位
Frederick G. Vogt
Interim Chief Executive Officer and President, General Counsel; Director
Igor P. Bilinsky
Chief Operating Officer
Corleen Roche
Chief Financial Officer and Principal Accounting Officer
Daniel Gordon Kirby
Chief Commercial Officer
Friedrich Graf Finckenstein
Chief Medical Officer
Raj K. Puri
Chief Regulatory Officer